Cargando…
Bone Sarcomas: From Biology to Targeted Therapies
Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514839/ https://www.ncbi.nlm.nih.gov/pubmed/23226965 http://dx.doi.org/10.1155/2012/301975 |
_version_ | 1782252086868574208 |
---|---|
author | Gaspar, Nathalie Di Giannatale, Angela Geoerger, Birgit Redini, Françoise Corradini, Nadège Enz-Werle, Natacha Tirode, Franck Marec-Berard, Perrine Gentet, Jean-Claude Laurence, Valérie Piperno-Neumann, Sophie Oberlin, Odile Brugieres, Laurence |
author_facet | Gaspar, Nathalie Di Giannatale, Angela Geoerger, Birgit Redini, Françoise Corradini, Nadège Enz-Werle, Natacha Tirode, Franck Marec-Berard, Perrine Gentet, Jean-Claude Laurence, Valérie Piperno-Neumann, Sophie Oberlin, Odile Brugieres, Laurence |
author_sort | Gaspar, Nathalie |
collection | PubMed |
description | Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour volume for Ewing sarcomas not operated), patients with multiple metastases at or those who relapsed. In order to develop new therapies against these rare tumours, we need to unveil the key driving factors and molecular abnormalities behind the malignant characteristics and to broaden our understanding of the phenomena sustaining the metastatic phenotype and treatment resistance in these tumours. In this paper, starting with the biology of these tumours, we will discuss potential therapeutic targets aimed at increasing local tumour control, limiting metastatic spread, and finally improving patient survival. |
format | Online Article Text |
id | pubmed-3514839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35148392012-12-07 Bone Sarcomas: From Biology to Targeted Therapies Gaspar, Nathalie Di Giannatale, Angela Geoerger, Birgit Redini, Françoise Corradini, Nadège Enz-Werle, Natacha Tirode, Franck Marec-Berard, Perrine Gentet, Jean-Claude Laurence, Valérie Piperno-Neumann, Sophie Oberlin, Odile Brugieres, Laurence Sarcoma Review Article Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour volume for Ewing sarcomas not operated), patients with multiple metastases at or those who relapsed. In order to develop new therapies against these rare tumours, we need to unveil the key driving factors and molecular abnormalities behind the malignant characteristics and to broaden our understanding of the phenomena sustaining the metastatic phenotype and treatment resistance in these tumours. In this paper, starting with the biology of these tumours, we will discuss potential therapeutic targets aimed at increasing local tumour control, limiting metastatic spread, and finally improving patient survival. Hindawi Publishing Corporation 2012 2012-11-27 /pmc/articles/PMC3514839/ /pubmed/23226965 http://dx.doi.org/10.1155/2012/301975 Text en Copyright © 2012 Nathalie Gaspar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Gaspar, Nathalie Di Giannatale, Angela Geoerger, Birgit Redini, Françoise Corradini, Nadège Enz-Werle, Natacha Tirode, Franck Marec-Berard, Perrine Gentet, Jean-Claude Laurence, Valérie Piperno-Neumann, Sophie Oberlin, Odile Brugieres, Laurence Bone Sarcomas: From Biology to Targeted Therapies |
title | Bone Sarcomas: From Biology to Targeted Therapies |
title_full | Bone Sarcomas: From Biology to Targeted Therapies |
title_fullStr | Bone Sarcomas: From Biology to Targeted Therapies |
title_full_unstemmed | Bone Sarcomas: From Biology to Targeted Therapies |
title_short | Bone Sarcomas: From Biology to Targeted Therapies |
title_sort | bone sarcomas: from biology to targeted therapies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514839/ https://www.ncbi.nlm.nih.gov/pubmed/23226965 http://dx.doi.org/10.1155/2012/301975 |
work_keys_str_mv | AT gasparnathalie bonesarcomasfrombiologytotargetedtherapies AT digiannataleangela bonesarcomasfrombiologytotargetedtherapies AT geoergerbirgit bonesarcomasfrombiologytotargetedtherapies AT redinifrancoise bonesarcomasfrombiologytotargetedtherapies AT corradininadege bonesarcomasfrombiologytotargetedtherapies AT enzwerlenatacha bonesarcomasfrombiologytotargetedtherapies AT tirodefranck bonesarcomasfrombiologytotargetedtherapies AT marecberardperrine bonesarcomasfrombiologytotargetedtherapies AT gentetjeanclaude bonesarcomasfrombiologytotargetedtherapies AT laurencevalerie bonesarcomasfrombiologytotargetedtherapies AT pipernoneumannsophie bonesarcomasfrombiologytotargetedtherapies AT oberlinodile bonesarcomasfrombiologytotargetedtherapies AT brugiereslaurence bonesarcomasfrombiologytotargetedtherapies |